Brief: Seikagaku initiates phase III study of SI-613
03/02/2017 06:27
Feb 3 (Reuters) - Seikagaku Corp 4548.T :
* Says co announces the start of Phase III study of SI-613,
a joint improving agent indicated for treatment of
osteoarthritis, in Japan
Source text in Japanese: https://goo.gl/wLpH3O
Further company coverage: 4548.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 62674724;
Reuters Messaging: Cheng.Li@thomsonreuters.com@reuters.net))